Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis-Reference-Cited by-同舟云学术

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis

Published:2022-12 Issue: Volume:174 Page:71-82
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Isomoto Kohsuke,Haratani Koji,Tsujikawa Takahiro,Makutani Yusuke,Kawakami Hisato,Takeda Masayuki,Yonesaka Kimio,Tanaka Kaoru,Iwasa Tsutomu,Hayashi Hidetoshi,Ito Akihiko,Nishio Kazuto,Nakagawa Kazuhiko

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference62 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

4. R.S. Herbst, P. Baas, D.W. Kim, E. Felip, J.L. Perez-Gracia, J.Y. Han, J. Molina, J.H. Kim, C.D. Arvis, M.J. Ahn, M. Majem, M.J. Fidler, G. de Castro, Jr., M. Garrido, G.M. Lubiniecki, Y. Shentu, E. Im, M. Dolled-Filhart, E.B. Garon, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet 387(10027) (2016) 1540-1550.

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T‐cell therapy in solid tumors;Cancer Science;2024-08-21

2. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer;Discover Oncology;2023-10-19

3. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE);Journal of Thoracic Oncology;2023-10

4. Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy;Translational Lung Cancer Research;2023-09

5. Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy;Expert Review of Anticancer Therapy;2023-07-24